DK2714006T3 - Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme - Google Patents

Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme Download PDF

Info

Publication number
DK2714006T3
DK2714006T3 DK12748245.3T DK12748245T DK2714006T3 DK 2714006 T3 DK2714006 T3 DK 2714006T3 DK 12748245 T DK12748245 T DK 12748245T DK 2714006 T3 DK2714006 T3 DK 2714006T3
Authority
DK
Denmark
Prior art keywords
treatment
gel formulations
testosterone gel
male hypogonadism
bioadhesive
Prior art date
Application number
DK12748245.3T
Other languages
Danish (da)
English (en)
Inventor
Wayne Kreppner
Siobhan Fogarty
Werner Oberegger
Paul José Pierre Marie MAES
Original Assignee
Acerus Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerus Biopharma Inc filed Critical Acerus Biopharma Inc
Application granted granted Critical
Publication of DK2714006T3 publication Critical patent/DK2714006T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12748245.3T 2011-05-15 2012-05-15 Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme DK2714006T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US201161486634P 2011-05-16 2011-05-16
PCT/IB2012/001112 WO2012156820A1 (en) 2011-05-15 2012-05-15 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Publications (1)

Publication Number Publication Date
DK2714006T3 true DK2714006T3 (da) 2021-03-15

Family

ID=46579248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12748245.3T DK2714006T3 (da) 2011-05-15 2012-05-15 Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme

Country Status (16)

Country Link
EP (3) EP3977982A1 (enExample)
JP (9) JP6152092B2 (enExample)
KR (10) KR20140045400A (enExample)
CN (4) CN109481394B (enExample)
AR (2) AR086409A1 (enExample)
AU (11) AU2012257492A1 (enExample)
BR (2) BR112013029336B1 (enExample)
CA (3) CA2836398C (enExample)
DK (1) DK2714006T3 (enExample)
EA (1) EA201391701A1 (enExample)
ES (1) ES2859784T3 (enExample)
IL (2) IL229401A0 (enExample)
MX (4) MX374398B (enExample)
PL (1) PL2714006T4 (enExample)
WO (2) WO2012156822A1 (enExample)
ZA (2) ZA201309264B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
JP6152092B2 (ja) * 2011-05-15 2017-06-28 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150297733A1 (en) * 2012-11-14 2015-10-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP4382165A3 (en) * 2013-10-07 2024-08-21 Antares Pharma, Inc. Hematocrit modulation through needle assisted jet injection of testosterone
EP4062918A1 (en) * 2014-02-19 2022-09-28 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
WO2016123317A1 (en) * 2015-01-28 2016-08-04 Prometheon Pharma, Llc Topical formulations of growth factors
EP4233873A3 (en) * 2015-06-29 2023-10-18 Lyra Therapeutics, Inc. Implantable scaffolds for treatment of sinusitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
AU2017206048B2 (en) * 2016-01-07 2023-04-13 Viramal Limited Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3021989A1 (en) 2016-04-25 2017-11-02 Marc Andrew Koska Medical delivery system
CA3026274A1 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
KR102387241B1 (ko) * 2016-06-03 2022-04-15 엠 이티 피 파마 아게 다공성 부형제를 갖는 비강용 약제학적 조성물
CA3050361A1 (en) 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
WO2018231028A1 (ko) * 2017-06-17 2018-12-20 엘지전자(주) 무선 통신 시스템에서 단말의 등록 방법 및 이를 위한 장치
WO2019099954A1 (en) 2017-11-17 2019-05-23 Koska Family Limited Systems and methods for fluid delivery manifolds
CN111386119A (zh) * 2017-11-27 2020-07-07 Aska制药株式会社 粉末鼻腔给药制剂
MX2020008147A (es) 2018-02-02 2020-10-28 Acerus Biopharma Inc Metodos de terapia de testosterona.
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
SG11202106306YA (en) * 2018-12-14 2021-07-29 Acerus Biopharma Inc Active ester derivatives of testosterone, compositions and uses thereof
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
IL302986A (en) * 2020-11-19 2023-07-01 Acousia Therapeutics Gmbh A non-aqueous gel preparation
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
KR100648536B1 (ko) * 1997-11-10 2006-11-24 셀러지 파마세우티칼스, 인크 침투 보강 및 자극 감소를 위한 계
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
MXPA04003359A (es) * 2001-10-12 2004-11-29 Cns Corporated Gel nasal hidratante y dispositivo aplicador.
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
PL1670433T3 (pl) * 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
AU2005313601B2 (en) * 2004-12-09 2012-05-24 Bayer Intellectual Property Gmbh Stabilisation of glucocorticoid esters with acids
CA2610708C (en) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
RU2480208C2 (ru) * 2006-10-04 2013-04-27 М Унд П Патент Акциенгезелльшафт Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров
AU2008231781B2 (en) * 2007-03-23 2012-09-20 Besins Healthcare Luxembourg Sarl Compositions and method for treating pediatric hypogonadism
EP2191833B1 (en) * 2007-09-20 2013-02-13 Shiseido Company, Ltd. Transdermally absorbable preparation
EP2060300B1 (en) * 2007-11-13 2015-04-15 Curadis GmbH C-19 steroids for therapeutic uses
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
JP6152092B2 (ja) * 2011-05-15 2017-06-28 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム

Also Published As

Publication number Publication date
MX363561B (es) 2019-03-27
AU2022202402A1 (en) 2022-05-12
KR20140045400A (ko) 2014-04-16
JP2021001206A (ja) 2021-01-07
MX2020008599A (es) 2022-08-31
MX395212B (es) 2025-03-21
KR20200118228A (ko) 2020-10-14
AU2024216312A1 (en) 2024-10-24
ES2859784T3 (es) 2021-10-04
KR20200028503A (ko) 2020-03-16
AU2020210227A1 (en) 2020-08-20
JP2022078222A (ja) 2022-05-24
ZA201309265B (en) 2016-01-27
EP2709588B1 (en) 2021-08-25
PL2714006T3 (pl) 2021-08-16
CA3034552C (en) 2023-02-07
AU2019203400A1 (en) 2019-08-01
CA2836398C (en) 2021-12-14
KR102568894B1 (ko) 2023-08-21
ZA201309264B (en) 2015-09-30
KR20210135003A (ko) 2021-11-11
JP2022105175A (ja) 2022-07-12
AU2020267162B2 (en) 2022-06-09
AR089553A1 (es) 2014-09-03
EP2714006A1 (en) 2014-04-09
AR086409A1 (es) 2013-12-11
JP6594924B2 (ja) 2019-10-23
KR20140033408A (ko) 2014-03-18
AU2019201618A1 (en) 2019-04-18
WO2012156820A9 (en) 2014-02-20
JP2014515038A (ja) 2014-06-26
EP2709588A1 (en) 2014-03-26
CA2836405A1 (en) 2012-11-22
CN103796636B (zh) 2019-04-05
KR20190006194A (ko) 2019-01-17
JP2020073469A (ja) 2020-05-14
JP6152092B2 (ja) 2017-06-28
BR112013029336B1 (pt) 2021-11-30
CN109481394A (zh) 2019-03-19
PL2714006T4 (pl) 2021-08-16
AU2012257492A1 (en) 2013-12-19
MX374398B (es) 2025-03-06
KR102088038B1 (ko) 2020-03-13
JP2020079257A (ja) 2020-05-28
BR112013029332A2 (pt) 2021-06-01
AU2017203470A1 (en) 2017-06-22
AU2020267162A1 (en) 2020-12-03
KR20240162608A (ko) 2024-11-15
KR20210029849A (ko) 2021-03-16
AU2017204182A1 (en) 2017-07-20
BR112013029336A2 (pt) 2020-08-11
CN103813784A (zh) 2014-05-21
AU2019203067A1 (en) 2019-05-23
IL229401A0 (en) 2014-01-30
MX2013013388A (es) 2014-09-15
EP3977982A1 (en) 2022-04-06
MX2013013369A (es) 2014-10-17
WO2012156822A1 (en) 2012-11-22
AU2012257490A1 (en) 2013-12-19
CA3034552A1 (en) 2012-11-22
JP7017254B2 (ja) 2022-02-08
KR20230041081A (ko) 2023-03-23
JP2017160204A (ja) 2017-09-14
MX2019003340A (es) 2019-07-04
WO2012156820A1 (en) 2012-11-22
CN109481394B (zh) 2023-05-05
KR20190117803A (ko) 2019-10-16
JP2018199701A (ja) 2018-12-20
CN103796636A (zh) 2014-05-14
IL229400A0 (en) 2014-01-30
CN110613679A (zh) 2019-12-27
JP2014513716A (ja) 2014-06-05
EP2714006B1 (en) 2020-12-09
CA2836398A1 (en) 2012-11-22
CA2836405C (en) 2021-09-07
EA201391701A1 (ru) 2014-04-30

Similar Documents

Publication Publication Date Title
DK2714006T3 (da) Intranasale bioadhæsive testosterongelformuleringer og anvendelse deraf til behandling af mandlig hypogonadisme
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2774616T3 (da) Anvendelse af roseburia i behandling og forebyggelse af fedmerelaterede sygdomme
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2624567T3 (da) Blokinddelingsfremgangsmåde og afkodningsindretning
IL235858A0 (en) Devices and scaffolds for tissue repair
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
DK2609956T3 (da) Midlertidigt foldbart kateteraggregat og dertil hørende fremgangsmåde
DK2521221T4 (da) Høreanordning og fremgangsmåde
DK2872419T3 (da) Fordelingsbeholder og tilsvarende fremgangsmåde
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
DK2552434T3 (da) Peptider og anvendelse deraf
LT2605789T (lt) Modifikuoti relaksino polipeptidai ir jų panaudojimas
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK3967868T3 (da) Væskeforstøver og fremgangsmåde
LT2895512T (lt) Žmogaus salelių amiloido polipeptido (hiapp) specifiniai antikūnai ir jų panaudojimas
PL2934093T3 (pl) Trwała transformacja populacji i sposób ochrony biologicznej z wykorzystaniem zasad haploinsuficjencji i poddominacji
DK2917231T3 (da) Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
HUE13837694T1 (hu) Daptomicin készítmények és alkalmazásaik
DK2549995T3 (da) Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin
IL234906A0 (en) Colchicine compositions, methods of production and methods of using them
PL2521445T3 (pl) Preparat i jego zastosowanie
DK2889365T3 (da) Fremgangsmåde til undersøgelse af mikroorganismer og indretning dertil
DK3363437T3 (da) Aminoindanforbindelser og anvendelse deraf i behandling af smerte